Renvistobart

DUBLIN--( BUSINESS WIRE )--The "Anti TIGIT Antibodies Clinical Trials & Market Opportunity Outlook 2028" report has been added to ResearchAndMarkets.com's offering. Anti TIGIT antibodies have emerged a promising approach in cancer immunotherapy, offering new hope for patients with various types of cancers, particularly solid cancers. TIGIT (T cell immunoreceptor with Ig and ITIM domains) is an inhibitory receptor expressed on T cells and natural killer (NK) cells, playing a crucial role in modulating immune responses. By targeting TIGIT, researchers aim to enhance the immune system's ability to recognize and eliminate cancer cells, potentially revolutionizing cancer treatment strategies. The therapeutic potential of TIGIT as a target for cancer immunotherapy lies in its function as an immune checkpoint molecule. When TIGIT interacts with its ligands, such as CD155 and CD112, it suppresses T cell sand NK cell activation, potentially allowing cancer cells to evade immune surveillance. By blocking this interaction with anti-TIGIT therapeutic approaches, researchers hope to reinvigorate the immune response against tumors, leading to improved clinical outcome for cancer patients. Among the various approaches for targeting TIGIT, monoclonal antibodies have emerged as the most widely used and promising agents. These antibodies are designed to specifically bind to TIGIT, preventing its interaction with its ligands and thus releasing the "breaks" on the immune system. Their high specificity and relatively low toxicity of antibodies make them attractive candidates for clinical development. The field of anti-TIGIT antibody development has seen rapid progress, with over 50 candidates currently in clinical development. This robust pipeline underscores the significant interest and potential of this approach in cancer treatment. Among these, more than five anti TIGIT antibodies have advanced to phase 3 clinical trials, representing the most advanced stage of clinical development before potential regulatory approval. These include Vibostolimab, Tiragolumab and Ociperlimab, developed by the pharmaceutical marker leaders, Merck Genentech and BeiGene, respectively. These phase 3 clinical trials are assessing the safety and efficacy of these anti-TIGIT antibodies in various cancer types, with a particular focus on non-small cell lung cancer (NSCLC). The emphasis on NSCLC is not surprising, given its high prevalence and the need for more effective treatment options. NSCLC represents a significant portion of lung cancer cases and has shown promising responses to immunotherapy approaches in the past. Several key factors are driving the market potential of anti-TIGIT antibodies. Firstly, there remains a substantial unmet medical need in cancer treatment, especially for patients who do not respond to or develop resistance to existing immunotherapies. Anti-TIGIT antibodies offer a novel mechanism of action that could address these challenges. Moreover, these antibodies show promising results in combination with established therapies like PD-1/L1 inhibitors, potentially expanding the market for both drug classes and improving treatment outcomes. This becomes visible in Merck's vision of developing a coformulation of its anti-TIGIT antibody Vibostolimab with its blockbuster anti-PD-1 antibody pembrolizumab for the treatment of various solid tumors. The broad applicability of anti-TIGIT antibodies across various cancer forms presents another significant market opportunity. While a majority of clinical trials currently focus on NSCLC, many other ongoing clinical trials are exploring their efficacy in other solid cancers tumors and hematological malignancies, which could lead to multiple approved indications, consequently increasing the anti-TIGIT antibody market size. As evident from the examples above, the competitive landscape for the anti-TIGIT antibody market is dynamic, with major pharmaceutical companies and biotechnology firms vying for market share. While Vibostolimab leverages the company's strong position in the immuno-oncology market, another, Domvanalimab, being developed by Gilead Sciences and Arcus Biosciences, benefits from a partnership between a major pharmaceutical company and a competent biopharmaceutical company. In conclusion, anti-TIGIT antibodies not only represent a significant advancement in cancer immunotherapy, but also present many opportunities for drug development and market expansion. With its potential to address unmet medical needs, broad applicability and alignment with personalized medicine, this emerging class of drugs is poised to capture a substantial portion of cancer immunotherapy market. Anti TIGIT Antibodies Clinical Trials & Market Opportunity Outlook 2028 Report Highlights: Anti TIGIT Antibodies in Clinical Trials: > 50 Antibodies First Anti TIGIT Antibody to Get Approval Within Next 5 Years Global Anti TIGIT Antibodies Clinical Pipeline Insight by Company, Indication and Phase Insight on More Than 50 Anti TIGIT Antibodies in Clinical Trials Anti TIGIT Antibodies Market Trends by Indication & Country Global Anti TIGIT Antibodies Market Dynamics Key Topics Covered: 1. Introduction to Anti TIGIT Antibody 1.1 Overview 1.2 Mechanism of Anti TIGIT Antibodies 1.3 Clinical Approaches to Target TIGIT 2. Global Anti TIGIT Antibodies Clinical Trials Overview 2.1 By Company 2.2 By Country 2.3 By Indication 2.4 By Patient Segment 2.5 By Phase 3. Global Anti TIGIT Antibodies Clinical Pipeline By Company, Indication and Phase 3.1 Research 3.2 Preclinical 3.3 Phase I 3.4 Phase I/II 3.5 Phase II 3.6 Phase III 4. Global Anti TIGIT Antibodies Market Outlook 4.1 Current Clinical & Market Trends 4.2 Future Market Outlook 5. Anti TIGIT Antibodies Market Trends by Indication 5.1 Cancer 5.2 Autoimmune & Inflammatory Disorders 5.3 Microbial Infections 6. Anti TIGIT Antibodies Market by Country 6.1 US 6.2 China 6.3 South Korea 6.4 Australia 6.5 UK 7. Combinations Approaches for TIGIT Therapy 8. TIGIT Co Inhibition with PD1 or PDL1 9. Global Anti TIGIT Antibodies Market Dynamics 9.1 Market Drivers 9.2 Commercialization Challenges 10. Competitive Landscape Akeso Biopharma BeiGene Bio-Thera Solutions Biotheus Compugen FutureGen Biopharmaceutical Merck Sharp & Dohme Nanjing Sanhome Pharmaceutical OriCell Therapeutics Phio Pharmaceuticals Roche Shanghai Henlius Biotech Shanghai Junshi Biosciences Simcere Pharmaceutical Group Tasrif Pharmaceutical For more information about this report visit https://www.researchandmarkets.com/r/sebifx About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Merck Research Laboratories in South San Francisco, California iStock, hapabapa The pharma said Thursday it is stopping a late-stage study of its blockbuster Keytruda plus the anti-TIGIT antibody vibostolimab and chemotherapy as a first-line treatment for extensive-stage small cell lung cancer, following a recommendation from an independent data monitoring committee. Merck announced Thursday that it is ending a late-stage trial of its blockbuster Keytruda, anti-TIGIT antibody vibostolimab and chemotherapy in the first line treatment of extensive-stage small cell lung cancer, after a recommendation from an independent data monitoring committee. The Phase III KeyVibe-008 trial compared the anti-TIGIT, Keytruda and chemo combination against Roche’s Tecentriq. However, extensive-stage small cell lung cancer (ES-SCLC) patients who were taking the combo encountered a higher rate of adverse events, including immune-related adverse events. In addition, data showed that the primary endpoint of overall survival (OS) met the pre-specified futility criteria. Merck said a comprehensive analysis is ongoing and that the company is notifying study investigators of the trial halt. Patients should stop ongoing treatment with the combination and be offered the option of being treated with Tencentriq, according to the announcement. Merck said it will share the study results with the scientific community. “Small cell lung cancer remains a difficult disease to treat, as evident by the seven percent five-year survival rate and limited advancements in treatment options,” Marjorie Green, senior vice president and head of oncology global clinical development for Merck Research Laboratories, said in a statement. “Innovative research plays a critical role in improving our understanding to help patients achieve better outcomes, and while we hoped the results would be different, we remain committed to investigating novel approaches to treat this debilitating disease.” This is not the only setback that Merck has run into for its anti-TIGIT combinations. Last year, Merck axed a Phase II study investigating the combo of Keytruda and vibostolimab which failed to reach statistical significance in progression-free survival in treating metastatic non-small cell lung cancer (NSCLC) patients with progressive disease after treatment with immunotherapy and chemotherapy. In May 2024, Merck also pulled the plug on a Phase III trial of a Keytruda and vibostolimab combo in skin cancer after a high rate of dropouts due to immune-mediated adverse events, which would have made reaching statistical significance unlikely. However, Merck is still working on its combination of vibostolimab and Keytruda, investigating the combination in three separate clinical trials to treat NSCLC. The company said the interim external data from the committee safety reviews have not resulted in any modifications and are undergoing “comprehensive safety monitoring.” Other pharmas have also encountered challenges with anti-TIGIT antibodies. Last month, Roche stopped a Phase III study of its antibody tiragolumab after revealing that it would not improve survival in patients with NSCLC. Last week , Massachusetts-based biotech Agenus announced that Bristol Myers Squibb returned the rights to a bispecific antibody that binds to TIGIT after forging a potential billion-dollar deal in 2021 .